WO2008110004A1 - Reoviruses having modified sequences - Google Patents
Reoviruses having modified sequences Download PDFInfo
- Publication number
- WO2008110004A1 WO2008110004A1 PCT/CA2008/000483 CA2008000483W WO2008110004A1 WO 2008110004 A1 WO2008110004 A1 WO 2008110004A1 CA 2008000483 W CA2008000483 W CA 2008000483W WO 2008110004 A1 WO2008110004 A1 WO 2008110004A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reovirus
- residue
- seq
- nucleic acid
- polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Definitions
- This invention relates to viruses, and more particularly to reoviruses having modified sequences.
- Reoviruses have a double-stranded, segmented RNA genome.
- the virions measure 60-80 nm in diameter and possess two concentric capsid shells, each of which is icosahedral.
- the mammalian reovirus genome consists of double-stranded RNA in 10 discrete segments with a total genome size of -23.5 kbp. The individual RNA segments vary in size.
- type 1 representsative strains include, for example, Lang (TlL)
- type 2 representsative strains include, for example, Jones (T2J)
- type 3 representsative strains include, for example, Dealing or Abney (T3D or T3A, respectively)
- the three serotypes are easily identifiable on the basis of neutralization and hemagglutinin-inhibition assays (see, for example, Sabin, 1959, Science, 130:966; Fields, et al., 1996, Fundamental Virology, 3rd Ed., Lippincott- Raven; Rosen, 1960, Am. J. Hyg., 71 :242; and Stanley, 1967, Br. Med. Bull, 23:150).
- reoviruses having modified nucleic acid and polypeptide sequences.
- Sequence modifications include, for example, modifications in one or more of the reovirus genome segments. Also provided are pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of using such reoviruses.
- the invention provides a reovirus that has a lambda-3 polypeptide having one or more amino acid modifications; a sigma-3 polypeptide having one or more amino acid modifications; a mu-1 polypeptide having one or more amino acid modifications; and/or a mu-2 polypeptide having one or more amino acid modifications.
- a reovirus can be, for example, non-naturally occurring.
- the invention provides a reovirus lambda-3 polypeptide having one or more amino acid modifications; a reovirus sigma-3 polypeptide having one or more amino acid modifications; a reovirus mu-1 polypeptide having one or more amino acid modifications; and/or a reovirus mu-2 polypeptide having one or more amino acid modifications.
- the one or more amino acid modifications in the lambda-3 polypeptide can be a VaI at residue 214, an Ala at residue 267, a Thr at residue 557, a Lys at residue 755, a Met at residue 756, a Pro at residue 926, a Pro at residue 963, a Leu at residue 979, an Arg at residue 1045, a VaI at residue 1071, or any combination thereof, numbered relative to GenBank Accession No. M24734.1. It is noted that, when the amino acid sequence is a VaI at residue 214 or a VaI at residue 1071, the amino acid sequence further includes at least one additional change in the amino acid sequence.
- the lambda-3 polypeptide includes the sequence shown in SEQ ID NO: 18.
- the one or more amino acid modifications in the sigma-3 polypeptide can be a Leu at residue 14, a Lys at residue 198, or any combination thereof, numbered relative to GenBank Accession No. K02739. It is noted that, when the amino acid sequence is a Leu at residue 14, the amino acid sequence further includes at least one additional change in the amino acid sequence.
- the sigma-3 polypeptide includes the sequence shown in SEQ ID NO: 14.
- the one or more amino acid modifications in the mu-1 polypeptide can be an Asp at residue 73 numbered relative to GenBank Accession No. M20161.1.
- the mu-1 polypeptide includes the sequence shown in SEQ ID NO:16.
- the amino acid modification mu-2 polypeptide can be a Ser at residue 528 numbered relative to GenBank Accession No. AF461684.1.
- the mu-1 polypeptide includes the sequence shown in SEQ ID NO:15.
- a reovirus as described herein having one or more modifications can further include a reovirus sigma-2 polypeptide.
- a sigma-2 polypeptide can have a Cys at one or more of position 70, 127, 195, 241, 255, 294, 296, or 340, numbered relative to GenBank Accession No. NP_694684.1.
- the sigma-2 polypeptide includes the sequence shown in SEQ ID NO: 12.
- the invention provides a reovirus that has a Ll genome segment having one or more nucleic acid modifications; a S4 genome segment having one or more nucleic acid modifications; a Ml genome segment having one or more nucleic acid modifications; and/or a M2 genome segment having one or more nucleic acid modifications.
- a reovirus can be, for example, non-naturally occurring.
- the invention provides a Ll genome segment having one or more nucleic acid modifications; a S4 genome segment having one or more nucleic acid modifications; a Ml genome segment having one or more nucleic acid modifications; and/or a M2 genome segment having one or more nucleic acid modifications.
- the one or more nucleic acid modifications in the Ll genome segment can be a T at position 660, a G at position 817, an A at position 1687, a G at position 2283, an ATG at positions 2284-2286, a C at position 2794, a C at position 2905, a C at position 2953, an A at position 3153, or a G at position 3231, numbered relative to GenBank Accession No. M24734.1.
- the Ll genome segment includes the sequence shown in SEQ ID NO:8.
- the one or more nucleic acid modifications in the S4 genome segment can be an A at position 74 and an A at position 624, numbered relative to GenBank
- the S4 genome segment includes the sequence shown in SEQ ID NO:4.
- the nucleic acid modification in the M2 genome segment can be a C at position 248, numbered relative to GenBank Accession No. M20161.1.
- the M2 genome segment includes the sequence shown in SEQ ID NO:6.
- the nucleic acid modification in the Ml genome segment can be a T at position 1595, numbered relative to GenBank Accession No. AF461684.1.
- the Ml genome segment includes the sequence shown in SEQ ID NO:5.
- a reovirus as described herein can include any modification or combination of modifications disclosed herein.
- a reovirus as described herein is a reassortant.
- a reovirus as described herein includes genomic segments having the sequences shown in SEQ ID NOs: 1-10 or the polypeptides shown in SEQ ID NOs:ll, 12, and 16-21, and either or both SEQ ID NO:13 or 14.
- a reovirus as disclosed herein is identified as IDAC Accession No. 190907-01.
- a reovirus as disclosed herein generally exhibits a growth advantage over a reovirus that does not contain a corresponding modification.
- Representative growth advantages include, but are not limited to, an increased rate of lysis; an increased size of plaque formation; an increased rate of RNA replication; an increased rate of RNA transcription; an increased rate of translation; an increased rate of virus assembly and/or packaging; an increased number of viral progeny; an increased ability of a reovirus to be taken up by a host cell; an increased or enhanced ability to uncoat; enhanced cell lysis or inducement to cell death including apoptosis, necrosis or autophagy; an enhanced ability to infect, lyse and kill human neoplastic cells lines; decreased immunogenicity in mammalian cells; differential susceptibility to interferon sensitivity; decreased toxicity toward the host; enhanced drug interaction; enhanced radiotherapy interaction; or the ability to release effective tumor epitopes
- the invention provides for methods of making an improved reovirus.
- Such methods generally include the steps of modifying the nucleic acid sequence of the reovirus, and selecting one or more improved reoviruses.
- the modifying step includes, for example, mutagenizing the reovirus.
- Representative types of mutagenesis include, without limitation, site-directed mutagenesis and chemical mutagenesis.
- the modifying step includes culturing the reovirus in a human cell line.
- An improved reovirus made according to the methods disclosed herein can be selected for an increased rate of lysis; an increased size of plaque formation; an increased rate of RNA replication; an increased rate of RNA transcription; an increased rate of translation; an increased rate of virus assembly and/or packaging; an increased number of viral progeny; an increased ability of a reovirus to be taken up by a host cell; an increased or enhanced ability to uncoat; enhanced cell lysis or inducement to cell death including apoptosis, necrosis or autophagy; an enhanced ability to infect, lyse and kill human neoplastic cells lines; decreased immunogenicity in mammalian cells; differential susceptibility to interferon sensitivity; decreased toxicity toward the host; enhanced drug interaction; enhanced radiotherapy interaction; or the ability to release effective tumor epitopes.
- the invention provides methods of treating a proliferative disorder in a patient.
- Such methods generally include administering a modified reovirus as described herein or a pharmaceutical composition containing such a modified reovirus to the patient.
- the reovirus is administered in an amount effective to cause oncolysis, and can be administered more than once.
- Representative routes of administration include, for example, direct injection, intravenously, intravascularly, intrathecally, intramuscularly, subcutaneously, intraperitoneally, topically, orally, rectally, vaginally, nasally, or by inhalation.
- the methods of treating a proliferative disorder as described herein can be accompanied by one of more procedures such as surgery, chemotherapy, radiation therapy, and immunosuppressive therapy.
- kits or article of manufacture that includes a reovirus having a modified sequence or any combination of genome segments having a modified sequence as disclosed herein.
- a kit also can include one or more agents as disclosed herein.
- Figure 1 is the nucleotide sequence of a representative Sl segment (SEQ ID NO:1), S2 segment (SEQ ID NO:2), S3 segment (SEQ ID NO:3) and S4 segment (SEQ ID NO:4).
- Figure 2 is the nucleotide sequence of a representative Ml segment (SEQ ID NO:5), M2 segment (SEQ ID NO:6) and M3 segment (SEQ ID NO:7).
- Figure 3 is the nucleotide sequence of a representative Ll segment (SEQ ID NO:8), L2 segment (SEQ ID NO:9) and L3 segment (SEQ ID NO: 10).
- Figure 4 is the amino acid sequence of a representative sigma-1 polypeptide (SEQ ID NO: 11), sigma-2 polypeptide (SEQ ID NO: 12), sigma-NS polypeptide (putative coding sequence 1, SEQ ED NO:13; putative coding sequence 2, SEQ ID NO:14) and sigma-3 polypeptide (SEQ ID NO: 15).
- Figure 5 is the amino acid sequence of a representative mu-2 polypeptide (SEQ ID NO: 16), mu-1 polypeptide (SEQ ID NO: 17) and mu-NS polypeptide (SEQ ID NO: 18).
- Figure 6 is the amino acid sequence of a representative lambda-3 polypeptide (SEQ ID NO: 16), mu-1 polypeptide (SEQ ID NO: 17) and mu-NS polypeptide (SEQ ID NO: 18).
- Figure 6 is the amino acid sequence of a representative lambda-3 polypeptide (SEQ ID NO:
- This disclosure describes modifications in the nucleotide and amino acid sequence of a reovirus. Such modifications are optionally selected to affect the virus's ability to replicate and/or package itself and, therefore, alter the infectivity and/or rate of replication of a reovirus.
- any of the genomic segments from any type 3 mammalian orthoreovirus can be modified as disclosed herein.
- Representative type 3 mammalian orthoreoviruses include, without limitation, Dearing and Abney strains. See, for example, ATCC Accession Nos. VR-232 and VR-824.
- Reoviruses that can be modified as disclosed herein include naturally-occurring reoviruses (e.g., isolated from a source in nature such as from a patient) and reassortant reoviruses (see, e.g., U.S. Patent No. 7,163,678).
- Lambda-3 represents the catalytic subunit of the reovirus RNA-dependent RNA polymerase, which mediates both plus- and minus-strand RNA synthesis within reovirus particles. Further modifications were observed in the M2 genome segment.
- the wild-type M2 genome segment encodes a 708 amino acid (76 kDa) protein designated mu-1, which is involved in the regulation of particle-bound transcription.
- this disclosure provides for Ll, S4, Ml, M2 or any combination of such genome segments that contain one or more nucleic acid modifications in the respective genome segment.
- a reovirus Ll genome segment having one or more nucleic acid modifications is provided herein; a reovirus S4 genome segment having one or more nucleic acid modifications; a reovirus Ml genome segment having one or more nucleic acid modifications; and/or a M2 genome segment having one or more nucleic acid modifications.
- a reovirus Ll genome segment has, for example, any combination of one or more of the following nucleotides: a T at position 660, a G at position 817, an A at position 1687, a G at position 2283, an ATG at positions 2284-2286, a C at position 2794, a C at position 2905, a C at position 2953, an A at position 3153, or a G at position 3231 (numbered relative to GenBank Accession No. M24734.1).
- a reovirus S4 genome segment has, for example, any combination of one or more of the following nucleotides: an A at position 74 or an A at position 624 (numbered relative to GenBank Accession No. K02739).
- a reovirus Ml genome segment has, for example, a T nucleotide at position 1595 (numbered relative to GenBank Accession No. AF461684.1).
- a reovirus M2 genome segment has, for example, a C nucleotide at position 248 (numbered relative to GenBank Accession No. M20161.1).
- the indicated nucleotide at the indicated position represents modifications when compared to other corresponding sequences available in public databases (e.g., GenBank Accession Nos. M24734.1, K02739, AF461684.1, and M20161.1).
- Areovirus lambda-3 polypeptide has, for example, any combination of one or more amino acid residues: a VaI at residue 214, an Ala at residue 267, a Thr at residue 557, a Lys at residue 755, a Met at residue 756, a Pro at residue 926, a Pro at residue 963, a Leu at residue 979, an Arg at residue 1045, or a VaI at residue 1071 (numbered relative to GenBank Accession No. M24734.1). It is noted that, when the polypeptide sequence comprises a VaI at residue 214 or a VaI at residue 1071, the polypeptide sequence further comprises at least one additional change in the amino acid sequence.
- a reovirus sigma-3 polypeptide has, for example, any combination of one or more amino acid residues: a Leu at residue 14 or a Lys at residue 198 (numbered relative to GenBank Accession No. K02739). It is noted that, when the polypeptide sequence comprises a Leu at residue 14, the polypeptide sequence further comprises at least one additional change in the amino acid sequence.
- Areovirus mu-1 polypeptide has, for example, an Asp at residue 73 (numbered relative to GenBank Accession No. AF461684.1).
- Areovirus mu-2 polypeptide has, for example, a Ser at residue 528 (numbered relative to GenBank Accession No. M20161.1).
- the indicated amino acid at the indicated position represents modifications when compared to other corresponding sequences in public databases (e.g., GenBank Accession Nos. M24734.1, K02739, AF461684.1, and M20161.1).
- a “non-naturally occurring" reovirus is a reovirus that has at least one nucleic acid or amino acid modification as compared to wild type sequences derived from, for example, a field isolate (e.g., a patient).
- "Non-naturally occurring" reovirus refers to a virus which has been manipulated or modified in the laboratory. Such manipulated or modified reoviruses include laboratory strains or mutagenized versions. These versions are distinguishable, in nucleic acid and/or amino acid sequence, from, for example, Dearing and Abney strains (e.g., ATCC VR- 824 and VF-232, respectively).
- a reovirus optionally contains an S2 genome segment, which encodes the sigma-2 polypeptide.
- a sigma-2 polypeptide for example, has a Cys at one or more or all of the following positions: 70, 127, 195, 241, 255, 294, 296 or 340 (numbered relative to GenBank Accession No. NP_694684.1 ).
- a modification generally occurs at the nucleic acid level, which may or may not manifest itself in the encoded polypeptide. Modifications to a nucleic acid include, without limitation, single or multiple nucleotide transitions (purine to purine or pyrimidine to pyrimidine) or transversions (purine to pyrimidine or vice versa) and single- or multiple-nucleotide deletions or insertions.
- a modification in a nucleic acid can result in one or more conservative or non-conservative amino acid substitutions in the encoded polypeptide, a shift in the reading frame of translation ("frame- shift) resulting in an entirely different polypeptide encoded from that point on, a premature stop codon resulting in a truncated polypeptide ("truncation"), or a modification in a reovirus nucleic acid may not change the encoded polypeptide at all ("silent” or "nonsense”). See, for example, Johnson & Overington, 1993, J. MoI. Biol, 233:716-38; Henikoff & Henikoff, 1992, Proc. Natl. Acad. Sci. USA, 89:10915-19; and U.S.
- nucleic acids from reovirus particles are isolated, for example, using standard methodologies, which are commercially available. See also, for example, Schiff et al., "Orthoreoviruses and Their Replication," Ch 52, in Fields Virology, Knipe & Howley, eds., 2006, Lippincott Williams & Wilkins.
- isolated nucleic acids refer to nucleic acids that are substantially separated from other nucleic acids with which they are usually associated.
- an "isolated" nucleic acid includes, without limitation, reoviral nucleic acid that is essentially free of non-reo viral (e.g., host cell) nucleic acid, or a reoviral genomic segment that is essentially free of nucleic acid corresponding to other genomic segments.
- an isolated nucleic acid includes an engineered nucleic acid such as recombinant or synthetic nucleic acids.
- Modifications are generated in the nucleic acid of a reovirus using any number of methods known in the art.
- site directed mutagenesis can be used to modify a reovirus nucleic acid sequence.
- One of the most common methods of site-directed mutagenesis is oligonucleotide- directed mutagenesis.
- oligonucleotide-directed mutagenesis an oligonucleotide encoding the desired change(s) in sequence is annealed to one strand of the DNA of interest and serves as a primer for initiation of DNA synthesis. In this manner, the oligonucleotide containing the sequence change is incorporated into the newly synthesized strand. See, for example, Kunkel, 1985, Proc.
- modified nucleic acids are generated using PCR or chemical synthesis, or polypeptides having the desired change in amino acid sequence can be chemically synthesized. See, for example, Bang & Kent, 2005, Proc. Natl. Acad. Sci. USA, 102:5014-9 and references therein. Selection on a cell type on which reovirus is not usually grown (e.g., human cells) and/or chemical mutagenesis (see, for example, Rudd & Lemay, 2005, J. Gen. Virology, 86:1489-97) also can be used to generate modifications in the nucleic acid of a reovirus.
- the modifications shown in Table 1 were generated by culturing reovirus on human cells (e.g., human embryonic kidney (HEK) 293 cells), which are not typically used in the art of culturing reovirus.
- human cells e.g., human embryonic kidney (HEK) 293 cells
- HEK human embryonic kidney
- cells that are commonly used to culture reovirus are described in, for example, Tyler, "Mammalian Reoviruses," Ch 53, page 1731-2, in Fields Virology, Knipe & Howley, eds., 2006, Lippincott Williams & Wilkins.
- the modifications described herein represent an adaptation by the reovirus to human cells. There was also a selection step at each of these plaque purification steps by selection the largest plaque (triple plaque purification), thus a growth or virulence advantage in these cells.
- virus particles are reconstituted using methods known in the art. See, for example, Schiff et al., "Orthoreoviruses and Their Replication," Ch 52, in Fields Virology, Knipe & Howley, eds., 2006, Lippincott Williams & Wilkins; Smith et al., 1969, Virology, 39(4):791-810; and U.S. Patent Nos. 7,186,542; 7,049,127; 6,808,916; and 6,528,305.
- Reoviruses having one or more modifications in their sequence are cultured in, for example, mouse L929 cells or neoplastic cells (e.g., MCF7 (ATCC Accession No. HTB-22), SKBR3 (ATCC Accession No. HTB-30), or MDA MB 468 (ATCC Accession No. HTB 132) cells), and selected based on any number of characteristics that may indicate, for example, a growth advantage over a reovirus that does not contain one or more modifications.
- Reoviruses are selected following culturing in a cell line (neoplastic or otherwise) and/or following infection of an animal model system.
- Such characteristics include, without limitation, an increased rate of lysis; an increased size of plaque formation; an increased rate of RNA replication; an increased rate of RNA transcription; an increased rate of translation; an increased rate of virus assembly and/or packaging; an increased number of viral progeny; an increased ability of a reovirus to be taken up by a host cell; an increased or enhanced ability to uncoat; enhanced cell lysis or inducement to cell death including apoptosis, necrosis or autophagy; an enhanced ability to infect, lyse and kill human neoplastic cells lines; decreased immunogenicity in mammalian cells; differential susceptibility to interferon sensitivity; decreased toxicity toward the host; enhanced drug interaction; enhanced radiotherapy interaction; or the ability to release effective tumor epitopes.
- reoviruses having a modified sequence are selected, for example, for the ability to lytically infect a mammalian cell having an active Ras pathway. See, for example, U.S. Patent No. 7,052,832.
- Reovirus particles are obtained using any number of methods known in the art. For example, reoviruses are cultured in L929 mouse fibroblast cells or human cells (e.g., HEK 293), and the viral particles purified using standard methodology.
- purified viral particles refers to virus particles that have been substantially separated from cellular components that naturally accompany it.
- virus particles are considered “purified” when they are at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, or 99%) by dry weight, free from the proteins and other cellular components with which the viruses are naturally associated.
- a reovirus having the nucleic acid sequence shown in Figures 1, 2 and 3 (SEQ ID NOs: 1- 10) and the amino acid sequence shown in Figures 4, 5, and 6 (SEQ ID NOs:l 1-20), which contain the nucleotide and amino acid modifications shown in Table 1 was deposited with the International Depositary Authority of Canada (IDAC, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington St., Winnipeg, Manitoba Canada R3E 3R2) on September 19, 2007, and assigned Accession No.
- reoviruses use a host cell's Ras pathway machinery to downregulate double-stranded RNA-activated protein kinase (PKR) and thus replicate in the cell.
- PLR protein-activated protein kinase
- methods have been developed for using reovirus to treat proliferative disorders in mammals.
- Representative mammals include mice, dogs, cats, sheep, goats, cows, horses, pigs, non-human primates, and humans.
- a "patient” includes any mammal with a proliferative disorder.
- a proliferative disorder is any cellular disorder in which the cells proliferate more rapidly than normal tissue growth.
- a “proliferating cell” is a cell that is proliferating more rapidly than normal cells.
- a proliferative disorder includes, but is not limited to, neoplasms, which are also referred to as tumors.
- a neoplasm includes, but is not limited to, pancreatic cancer, breast cancer, brain cancer (e.g., glioblastoma), lung cancer, prostate cancer, colorectal cancer, thyroid cancer, renal cancer, adrenal cancer, liver cancer, neurofibromatosis, and leukemia.
- a neoplasm includes a solid neoplasm (e.g. sarcoma or carcinoma) or a cancerous growth affecting the hematopoietic system (e.g., lymphoma or leukemia).
- Other proliferative disorders include, but are not limited to neurofibromatosis.
- the proliferating cells have a mutation in which the Ras gene (or an element of the Ras signaling pathway) is activated, either directly (e.g., by an activating mutation in Ras) or indirectly (e.g., by activation of an upstream or downstream element in the Ras pathway).
- Activation of an upstream element in the Ras pathway includes, for example, transformation with epidermal growth factor receptor (EGFR) or Sos. See, for example, Wiessmuller & Wittinghofer, 1994, Cellular Signaling, 6(3):247-267; and Barbacid, 1987, Ann. Rev. Biochem., 56, 779-827.
- EGFR epidermal growth factor receptor
- Activation of a downstream element in the Ras pathway includes, for example, a mutation within B-Raf. See, for example, Brose et al., 2002, Cancer Res., 62:6997-7000.
- reovirus is useful for treating proliferative disorders caused by mutations or dysregulation of PKR. See, for example, Strong et al., 1998, EiWSO J, 17:3351-662.
- a reovirus having a modified sequence as disclosed herein is administered to a mammal that has a proliferative disorder.
- administration refers to delivery of a reovirus such that the reovirus contacts the proliferating cells.
- a reovirus is administered by direct injection.
- a reovirus is administered intravenously or intravascularly.
- a reovirus is administered in a manner such that it is transported systemically through the body of the mammal to thereby reach the neoplasm (e.g., intrathecally, intravenously, intramuscularly, subcutaneously, or intra- peritoneally).
- a reovirus also is administered locally including, for example, topically (e.g., for melanoma), orally (e.g., for oral or esophageal neoplasm), rectally (e.g., for colorectal neoplasm), vaginally (e.g., for cervical or vaginal neoplasm), nasally or by inhalation (e.g., for lung neoplasm).
- a reovirus is optionally administered by more than one route and/or to more than one location in an individual. Targeted administration may be used to administer a reovirus.
- dendritic cells containing a reovirus may be administered to a subject. See, for example, US Publication No.
- carrier cells may be used to target cells of a proliferative disorder and prevent immune recognition of a reovirus which they carry. See, for example, Qiao et al., 2008, Nature Med, 14:37-44; and WO 2008/009115.
- a reovirus having a modified sequence as disclosed herein is administered in an amount that is sufficient to treat the proliferative disorder (e.g., an "effective amount").
- a proliferative disorder is "treated" when administration of a reovirus having a modified sequence to proliferating cells affects one or more symptoms or clinical signs of the disorder including, e.g., increasing lysis (e.g., "oncolysis") of the cells, reducing the number of proliferating cells, reducing the size or progression of a neoplasm, reducing pain associated with the neoplasm, as compared to the signs or symptoms in the absence of the treatment.
- the term "oncolysis” means at least 10% of the proliferating cells are lysed (e.g., at least 20%, 30%, 40%, 50%, or 75% of the cells are lysed).
- the percentage of lysis can be determined, for example, by measuring the reduction in the size of a neoplasm or in the number of proliferating cells in a mammal, or by measuring the amount of lysis of cells in vitro (e.g., from a biopsy of the proliferating cells).
- An effective amount of a reovirus having a modified sequence is determined on an individual basis and is based, at least in part, on the particular reovirus used; the individual's size, age, gender; and the size and other characteristics of the proliferating cells.
- plaque forming units for treatment of a human, approximately 10 3 to 10 12 plaque forming units (PFU) of a reovirus is used, depending on the type, size and number of proliferating cells or neoplasms present.
- the effective amount can be from about 1.0 PFU/kg body weight to about 10 15 PFU /kg body weight (e.g., from about 10 2 PFU /kg body weight to about 10° PFU /kg body weight).
- a reovirus is administered in a single dose or in multiple doses (e.g., two, three, four, six, or more doses). Multiple doses are administered concurrently or consecutively (e.g., over a period of days or weeks). Treatment with a reovirus having a modified sequence lasts from several days to several months or until diminution of the disease is achieved.
- a reovirus having a modified sequence as disclosed herein is optionally administered in conjunction with surgery or removal of proliferating cells (e.g., a neoplasm). It also is contemplated that a reovirus having a modified sequence is optionally administered in conjunction with or in addition to radiation therapy. It is further contemplated that a reovirus having a modified sequence is optionally administered in conjunction with or in addition to known anticancer compounds, chemotherapeutic agents, and/or immunosuppressive agents.
- Such agents include, but are not limited to, 5-fluorouracil, mitomycin C, methotrexate, hydroxyurea, gemcitabine, cyclophosphamide, dacarbazine, mitoxantrone, anthracyclins (Epirubicin, Irinotecan, and Doxurubicin), antibodies to receptors such as herceptin, topoisomerase inhibitors such as etoposide or camptothecin, pregnasome, platinum compounds such as carboplatin and cisplatin, taxanes such as taxol and taxotere, hormone therapies such as tamoxifen and anti- estrogens, interleukins, interferons, aromatase inhibitors, progestational agents, LHRH analogs, mTOR inhibitors (e.g., rapamycin and derivatives thereof; see, for example, Homicsko et al., 2005, Cancer Res., 65:6882-90; and Rao et al.,
- a reovirus having a modified sequence is administered in conjunction with an agent that can increase endothelial permeability and/or decrease interstitial fluid pressure.
- agents include, for example, TNF- ⁇ . See, for example, Sacchi et al., 2006, Clin. Cancer Res., 12:175-182. It is contemplated that a reovirus having a modified sequence can be administered in conjunction with any combination of the therapies and agents described herein.
- compositions that include one or more reoviruses, at least one of which has a modified sequence as described herein, are provided. See, for example, U.S. Patent No. 6,576,234.
- a pharmaceutical composition typically includes a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier includes a solid, semi-solid, or liquid material that acts as a vehicle, carrier or medium for the reovirus.
- compositions containing a reovirus having a modified sequence are in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
- suitable carriers include phosphate-buffered saline or another physiologically acceptable buffer, lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
- a pharmaceutical composition additionally can include, without limitation, lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
- compositions of the invention can be formulated to provide quick, sustained or delayed release of a reovirus having a modified sequence after administration by employing procedures known in the art.
- suitable formulations for use in a pharmaceutical composition are found in Remington: The Science and Practice of Pharmacy (2003, Gennaro & Gennaro, eds., Lippincott Williams & Wilkens).
- a reovirus having a modified sequence is mixed with a pharmaceutical carrier to form a solid composition.
- tablets or pills are coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- a tablet or pill comprises an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components for example, are separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
- Liquid formulations that include a reovirus having a modified sequence for oral administration or for injection generally include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as corn oil, cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. These liquid or solid compositions optionally contain suitable pharmaceutically acceptable excipients as described herein. Such compositions are administered, for example, by the oral or nasal respiratory route for local or systemic effect.
- compositions in pharmaceutically acceptable solvents are nebulized by use of inert gases. Nebulized solutions are inhaled, for example, directly from the nebulizing device, from an attached face mask tent, or from an intermittent positive pressure breathing machine. Solution, suspension, or powder compositions are administered, orally or nasally, for example, from devices which deliver the formulation in an appropriate manner.
- Another formulation that is employed in the methods taught herein employs transdermal delivery devices ("patches"). Such transdermal patches are used to provide continuous or discontinuous infusion of a reovirus having a modified sequence.
- the construction and use of transdermal patches for the delivery of pharmaceutical agents are perfo ⁇ ned according to methods known in the art. See, for example, U.S. Patent No. 5,023,252. Such patches are constructed for continuous, pulsatile, or on-demand delivery of a reovirus having a modified sequence.
- a reovirus having a modified sequence is optionally chemically or biochemically pretreated (e.g., by treatment with a protease such as chymotrypsin or trypsin) prior to administration (e.g., prior to inclusion in the pharmaceutical composition). Pretreatment with a protease removes the outer coat or capsid of the virus and can be used to increase the infectivity of the virus. Additionally or alternatively, a reovirus having a modified sequence is coated in a liposome or micelle to reduce or prevent an immune response in a mammal that has developed immunity toward a reovirus. Such reoviruses are referred to as "immunoprotected reoviruses.” See, for example, U.S. Patent Nos. 6,565,831 and 7,014,847.
- a reovirus having a modified sequence or a pharmaceutical composition comprising such a reovirus can be packaged into a kit. It is contemplated that a kit optionally includes one or more chemotherapeutic agents and/or immunosuppressive agents (e.g., anti-antireovirus antibodies).
- a pharmaceutical composition for example, is formulated in a unit dosage form.
- unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of a reovirus having a modified sequence calculated to produce the desired therapeutic effect in association with a suitable pharmaceutically acceptable carrier.
- HEK 293 S Master Cell Bank MBB
- HEK 293 cells were maintained in Serum Free Medium (HEK 293 SFM II) supplemented with L-glutamine.
- HEK 293 cells were expanded and seeded into three 15 L spinner flasks, and further expanded until there was 12 L in each of the three flasks.
- Infection of the HEK 293 cells by reovirus was performed by direct inoculation of the virus into the cell culture. The virus was harvested when the viability of the HEK 293 S cells had decreased by 20-50% postinfection.
- the virus material from all three spinners was pooled in a single sterile container and agitated to create a homogeneous mixture. Three liters of the pooled cell suspension was removed, transferred to conical tubes, and centrifuged at -3000 rpm for 15 minutes. The cells were then resuspended with 100 mL of clarified conditioned medium, snap frozen in an alcohol-dry ice bath three times, and then filled into sterile, labeled cryovials for use as a seed stock.
- a viral stock was prepared by performing a three-time plaque purification.
- Adherent HEK 293 S cells were plated onto 6-well tissue culture plates, infected with the seed stock described above, and two of the largest plaques were picked. These two plaques were separately amplified and harvested and two of the largest plaques were picked again. This procedure was repeated again for a total of three times. Of the two plaques, one was selected as seed stock for subsequent expansions.
- HEK 293 SFM II HEK 293 Serum Free Medium supplemented with L-glutamine.
- Cells were expanded from T-flasks up to multiple 3 L spinner flasks.
- the infection was performed by first diluting the plaque-purified virus in HEK 293 SFM media and then adding 8 to 12 mL of the diluted virus into the cell culture.
- the virus was harvested when the viability of the HEK 293 S cells had decreased by 20-50% following infection, and microscopic examination of each of the spinners confirmed the lack of microbial contamination and that a cytopathic effect (CPE) was present in the cells.
- CPE cytopathic effect
- CPE was indicated by cells having a swollen and granular appearance.
- the material from the spinners was pooled in a single sterile container, agitated to create a homogeneous mixture, and a bulk harvest sample removed.
- the remaining pooled cell suspension was transferred to conical tubes and centrifuged at -3000 rpm for 15 minutes.
- the cells were then resuspended with 400 mL of clarified conditioned medium, and the concentrated cell suspension was snap-frozen in an alcohol-dry ice bath three times to lyse the cells and then filled into sterile, labeled cryovials for use in sequencing reactions.
- RNA strands were sequenced from both directions, and the sequence of each of the 10 genomic segments was assembled from the overlapping contigs.
- the assembled sequence of each genomic segment was used in a BLAST search of the NCBI database (ncbi.nlm.nih.gov on the World Wide Web). Alignments with three or four different reovirus sequences found in the NCBI database were examined and the alignment having the highest amount of homology was used for further analysis.
- the polymorphisms or modifications compared to other reported sequences are shown in Table 1. Those modifications that are unique to the selected reovirus strain are indicated with an asterisk in Table 1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2009009598A MX2009009598A (en) | 2007-03-12 | 2008-03-11 | Reoviruses having modified sequences. |
ES08733587.3T ES2548442T3 (en) | 2007-03-12 | 2008-03-11 | Reoviruses that have modified sequences |
CA2678721A CA2678721C (en) | 2007-03-12 | 2008-03-11 | Reoviruses having modified sequences |
DK08733587.3T DK2132315T3 (en) | 2007-03-12 | 2008-03-11 | Reoviruses with modified sequences |
JP2009552983A JP5577103B2 (en) | 2007-03-12 | 2008-03-11 | Reovirus with modified sequence |
EP08733587.3A EP2132315B1 (en) | 2007-03-12 | 2008-03-11 | Reoviruses having modified sequences |
AU2008226291A AU2008226291B2 (en) | 2007-03-12 | 2008-03-14 | Reoviruses having modified sequences |
IL200353A IL200353A (en) | 2007-03-12 | 2009-08-12 | Reoviruses having modified sequences |
ZA2009/05951A ZA200905951B (en) | 2007-03-12 | 2009-08-27 | Reoviruses having modified sequences |
HK09112061.0A HK1132761A1 (en) | 2007-03-12 | 2009-12-22 | Reoviruses having modified sequences |
IL221700A IL221700A0 (en) | 2007-03-12 | 2012-08-30 | Reoviruses having modified sequences |
IL221701A IL221701A0 (en) | 2007-03-12 | 2012-08-30 | Reoviruses having modified sequences |
IL221702A IL221702A0 (en) | 2007-03-12 | 2012-08-30 | Reoviruses having modified sequences |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89442507P | 2007-03-12 | 2007-03-12 | |
US60/894,425 | 2007-03-12 | ||
US98956807P | 2007-11-21 | 2007-11-21 | |
US60/989,568 | 2007-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008110004A1 true WO2008110004A1 (en) | 2008-09-18 |
Family
ID=39758956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2008/000483 WO2008110004A1 (en) | 2007-03-12 | 2008-03-11 | Reoviruses having modified sequences |
Country Status (17)
Country | Link |
---|---|
US (5) | US7803385B2 (en) |
EP (2) | EP2952583A1 (en) |
JP (1) | JP5577103B2 (en) |
KR (1) | KR101647843B1 (en) |
CN (1) | CN103710359A (en) |
AR (1) | AR066395A1 (en) |
AU (1) | AU2008226291B2 (en) |
CA (1) | CA2678721C (en) |
DK (1) | DK2132315T3 (en) |
ES (1) | ES2548442T3 (en) |
HK (1) | HK1132761A1 (en) |
IL (4) | IL200353A (en) |
MX (2) | MX2009009598A (en) |
SG (1) | SG191602A1 (en) |
TW (1) | TW200904979A (en) |
WO (1) | WO2008110004A1 (en) |
ZA (1) | ZA200905951B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010067013A1 (en) * | 2008-12-11 | 2010-06-17 | Biomerieux | Novel isolated reovirus, and detection methods and kits |
US20110150928A1 (en) * | 2008-06-26 | 2011-06-23 | Biomune Company | Unique avian reoviridae |
WO2015070323A1 (en) | 2013-11-15 | 2015-05-21 | Oncolytics Biotech Inc. | Oncolytic viruses and increased cancer treatment regimens |
US11077157B2 (en) | 2016-02-16 | 2021-08-03 | Osaka University | Medicinal composition for treating fibrosis |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
DK2132315T3 (en) | 2007-03-12 | 2015-10-19 | Oncolytics Biotech Inc | Reoviruses with modified sequences |
EP2211880A4 (en) * | 2007-10-22 | 2012-11-14 | Oncolytics Biotech Inc | Treatment regime for proliferative disorders |
WO2009143611A1 (en) * | 2008-05-27 | 2009-12-03 | Oncolytics Biotech Inc. | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
AU2009253682B2 (en) * | 2008-05-27 | 2015-09-17 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
CA2776386C (en) | 2009-10-02 | 2018-02-27 | The Trustees Of Columbia University In The City Of New York | Piscine reovirus immunogenic compositions |
US9044498B2 (en) * | 2010-12-02 | 2015-06-02 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
SG190418A1 (en) * | 2010-12-02 | 2013-07-31 | Oncolytics Biotech Inc | Liquid viral formulations |
CN103492557B (en) * | 2011-04-29 | 2015-07-29 | 昂科利蒂克斯生物科技公司 | Use the method for gel permeation chromatography purified virus |
US9660989B1 (en) | 2014-01-31 | 2017-05-23 | Google Inc. | Internet-wide identity management widget |
WO2019237063A1 (en) * | 2018-06-07 | 2019-12-12 | Emory University | Modified reoviruses, particles, and uses in treating proliferative disorders |
KR102401077B1 (en) | 2019-01-25 | 2022-05-24 | 바이로큐어 주식회사 | Pharmaceutical Composition for preventing or treating cancer comprising Squirrel fibroma virus and Reovirus |
US20240041959A1 (en) * | 2020-12-22 | 2024-02-08 | Virocure, Inc. | Novel modified reovirus and use thereof |
WO2023048532A1 (en) * | 2021-09-24 | 2023-03-30 | 바이로큐어 주식회사 | Novel reovirus-based vaccine platform and use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US6136307A (en) | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
WO2007099401A2 (en) * | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US6565831B1 (en) * | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
WO2002039117A1 (en) | 2000-11-09 | 2002-05-16 | Oncolytics Biotech, Inc. | Methods for the treatment of cellular proliferative disorders |
JP2004519431A (en) * | 2000-12-01 | 2004-07-02 | ユニバーシティ・オブ・オタワ | Oncolytic virus |
JP4087712B2 (en) * | 2001-03-16 | 2008-05-21 | オンコリティクス バイオテック, インコーポレイティッド | Methods for extracting viruses from cell cultures |
US7163678B2 (en) | 2002-11-07 | 2007-01-16 | Oncolytics Biotech Inc. | Reovirus for the treatment of ral-mediated cellular proliferative disorders |
WO2005111200A1 (en) * | 2004-05-17 | 2005-11-24 | Universite De Montreal | Novel strains of reoviruses and methods of uses thereof |
AU2005257107A1 (en) * | 2004-06-24 | 2006-01-05 | Dnavec Research Inc. | Anticancer agent containing dendritic cell having RNA virus transferred thereinto |
US20100086522A1 (en) | 2006-07-18 | 2010-04-08 | Ottawa Health Research Institute | Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses |
DK2132315T3 (en) | 2007-03-12 | 2015-10-19 | Oncolytics Biotech Inc | Reoviruses with modified sequences |
WO2009143611A1 (en) * | 2008-05-27 | 2009-12-03 | Oncolytics Biotech Inc. | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
SG190418A1 (en) * | 2010-12-02 | 2013-07-31 | Oncolytics Biotech Inc | Liquid viral formulations |
US9044498B2 (en) * | 2010-12-02 | 2015-06-02 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
-
2008
- 2008-03-11 DK DK08733587.3T patent/DK2132315T3/en active
- 2008-03-11 JP JP2009552983A patent/JP5577103B2/en active Active
- 2008-03-11 SG SG2013040027A patent/SG191602A1/en unknown
- 2008-03-11 MX MX2009009598A patent/MX2009009598A/en active IP Right Grant
- 2008-03-11 EP EP15176066.7A patent/EP2952583A1/en not_active Withdrawn
- 2008-03-11 ES ES08733587.3T patent/ES2548442T3/en active Active
- 2008-03-11 CA CA2678721A patent/CA2678721C/en active Active
- 2008-03-11 WO PCT/CA2008/000483 patent/WO2008110004A1/en active Application Filing
- 2008-03-11 US US12/046,095 patent/US7803385B2/en active Active
- 2008-03-11 KR KR1020097019418A patent/KR101647843B1/en active IP Right Grant
- 2008-03-11 CN CN201310353609.2A patent/CN103710359A/en active Pending
- 2008-03-11 EP EP08733587.3A patent/EP2132315B1/en active Active
- 2008-03-12 AR ARP080101017A patent/AR066395A1/en unknown
- 2008-03-12 TW TW097108636A patent/TW200904979A/en unknown
- 2008-03-14 AU AU2008226291A patent/AU2008226291B2/en active Active
-
2009
- 2009-08-12 IL IL200353A patent/IL200353A/en active IP Right Grant
- 2009-08-27 ZA ZA2009/05951A patent/ZA200905951B/en unknown
- 2009-09-08 MX MX2013013938A patent/MX346950B/en unknown
- 2009-12-22 HK HK09112061.0A patent/HK1132761A1/en unknown
-
2010
- 2010-08-02 US US12/848,684 patent/US8691241B2/en active Active
-
2012
- 2012-08-30 IL IL221700A patent/IL221700A0/en unknown
- 2012-08-30 IL IL221702A patent/IL221702A0/en unknown
- 2012-08-30 IL IL221701A patent/IL221701A0/en unknown
-
2014
- 2014-02-13 US US14/179,840 patent/US10039827B2/en active Active
-
2018
- 2018-07-03 US US16/027,206 patent/US10596260B2/en active Active
-
2020
- 2020-02-13 US US16/790,114 patent/US11246930B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US6136307A (en) | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
US6261555B1 (en) | 1997-08-13 | 2001-07-17 | Oncolytics Biotech, Inc. | Reovirus for the treatment of neoplasia |
US6344195B1 (en) | 1997-08-13 | 2002-02-05 | Oncolytics Biotech, Inc. | Reovirus for the treatment of neoplasia |
US6576234B2 (en) | 1997-08-13 | 2003-06-10 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US6811775B2 (en) | 1999-02-24 | 2004-11-02 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
WO2007099401A2 (en) * | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
Non-Patent Citations (7)
Title |
---|
BARBACID, ANN. REV. BIOCHE171., vol. 56, 1987, pages 779 - 827 |
DERMODY T.S. ET AL.: "The S2 Gene Nucleotide Sequences of Prototype Strains of the Three Reovirus Serotypes: Characterization of Reovirus Core Protein sigma2", JOURNAL OF VIROLOGY, vol. 65, no. 11, January 1991 (1991-01-01), pages 5721 - 5731, XP002105958 * |
MCCUTCHEON A.M. ET AL.: "Mammalian Reovirus M3 Gene Sequences and Conservation of Coiled-Coil Motifs near the Carboxyl Terminus of the muNS Protein", VIROLOGY, vol. 264, November 1999 (1999-11-01), pages 16 - 24, XP004439718 * |
RICHARDSON M.A. ET AL.: "Nucleotide sequence of reovirus genome segment S3, encoding non-structural protein sigma NS", NUCLEIC ACIDS RESEARCH, vol. 11, no. 18, September 1983 (1983-09-01), pages 6399 - 6408, XP008117667 * |
See also references of EP2132315A4 |
WIENER J.R. ET AL.: "The sequence of the S2 genome segments of reovirus serotype 3 and of the dsRNA-negative mutant ts447", VIROLOGY, vol. 170, no. 1, May 1989 (1989-05-01), pages 340 - 341, XP023049425 * |
WIESSMULLER; WITTINGHOFER, CELLULAR SIGNALING, vol. 6, no. 3, 1994, pages 247 - 267 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110150928A1 (en) * | 2008-06-26 | 2011-06-23 | Biomune Company | Unique avian reoviridae |
US9273287B2 (en) * | 2008-06-26 | 2016-03-01 | Biomune Company | Avian reoviridae and vaccines thereof |
WO2010067013A1 (en) * | 2008-12-11 | 2010-06-17 | Biomerieux | Novel isolated reovirus, and detection methods and kits |
FR2939807A1 (en) * | 2008-12-11 | 2010-06-18 | Biomerieux Sa | NEW ISOLATED REOVIRUS, METHODS AND DETECTION KITS |
WO2015070323A1 (en) | 2013-11-15 | 2015-05-21 | Oncolytics Biotech Inc. | Oncolytic viruses and increased cancer treatment regimens |
US11077157B2 (en) | 2016-02-16 | 2021-08-03 | Osaka University | Medicinal composition for treating fibrosis |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11246930B2 (en) | Reoviruses having modified sequences | |
EP1586634B1 (en) | Method of producing infectious reovirus | |
AU2008253505B2 (en) | Mutant reoviruses and methods of making and using | |
EP1227828A1 (en) | Viruses for the treatment of cellular proliferative disorders | |
AU2001275628A1 (en) | Method of producing infectious reovirus | |
CA2723580A1 (en) | Modulating interstitial pressure and oncolytic viral delivery and distribution | |
US8470312B2 (en) | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy | |
AU2013201835A1 (en) | Reoviruses having modified sequences | |
CN101627122A (en) | Reoviruses having modified sequences |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880007670.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08733587 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200353 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2678721 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009552983 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008226291 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5769/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/009598 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097019418 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008733587 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008226291 Country of ref document: AU Date of ref document: 20080311 Kind code of ref document: A |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 221702 Country of ref document: IL Ref document number: 221701 Country of ref document: IL Ref document number: 221700 Country of ref document: IL |